Country: Armenia
Language: English
Source: Դեղերի և բժշկական տեխնոլոգիաների փորձագիտական կենտրոնի գործունեության Հայաստանի Հանրապետությունում
amoxicillin (amoxicillin trihydrate), clavulanic acid (potassium clavulanate)
Apotex Inc.
J01CR02
amoxicillin (amoxicillin trihydrate), clavulanic acid (potassium clavulanate)
250mg+125mg
tablets
(100) plastic container
Prescription
Registered
2015-06-09
ÿþýüûúùøú÷ ýöõùôõ ûõùó ÿþýü û¿ úù ø÷ úý÷ÞûøÈþ ð÷Çýþøõùðý÷ ÿÍ öÿÙÓöÒÙÑÐ îÖöÏ öõúôóòóññóðâîñþíìñþðóò öòóï ëþêñüéè þðï ÿúÚïüÞ ùúÞ ÙÞþñ æìèØüðèóúð çæÿ ëÝóè ñüþùñüé óè ïüèóýðüï èØüòóùóòþññÜ ùúÞ òúðèìõüÞè× ëÝóè ñüþùñüé óè þ èìõõþÞÜ þðï Úóññ ðúé éüññ Üúì üíüÞÜéÝóðý þêúìé öÿÙÓ öÒÙÑÐîÖöÏ× îúðéþòé ÜúìÞ ïúòéúÞ úÞ ØÝþÞõþòóèé óù Üúì Ýþíü þðÜ Èìüèéóúðè þêúìé éÝü ïÞìý× õÃýûù ùôðÞ øÈüðúõùðý÷ ÁÔæà àÔá íáåêéæàêìç êß ãßáå ÐìóÆ öÿÙÓöÒÙÑÐ îÖöÏ óè þð þðéóêóúéóò ÚÝóòÝ óè ìèüï éú éÞüþé íþÞóúìè êþòéüÞóþñ óðùüòéóúðèÊ þè ïüéüÞõóðüï êÜ ÜúìÞ ïúòéúÞ× Ðé òúðéþóðè éÚú õüïóòóðþñ óðýÞüïóüðéèÎ úðü óè þ Øüðóòóññóð òþññüï þõúôóòóññóð þðï éÝü úéÝüÞ óè òñþíìñþðóò þòóï× ÁÔæà êà åìáßÆ öÿÙÓöÒÙÑÐ îÖöÏ ÚúÞÌè óð å ÚþÜè× öõúôóòóññóð óðéüÞùüÞüè ÚóéÝ êþòéüÞóþñ òüññ Úþññ ýÞúÚéÝ ñüþïóðý éú êþòéüÞóþñ ïüþéÝ× öÿÙÓ öÒÙÑÐ îÖöÏ óðéüÞùüÞüè ÚóéÝ êþòéüÞóþñ üðÄÜõüè ÚÝóòÝ ïüèéÞúÜ þðéóêóúéóòè þññúÚóðý þðéóêóúéóòè éú òúðéóðìü Ìóññóðý êþòéüÞóþ× ÁÔáç êà ßÔìãèå çìà âá ãßáåÆ Âú ðúé ìèü öÿÙÓöÒÙÑÐ îÖöÏóùÎ i Ðù Üúì úÞ ÜúìÞ òÝóñï òìÞÞüðéñÜ Ýþíü úÞ Ýþíü Ýþï þ ÝóèéúÞÜ úù þð þññüÞýÜ éú þõúôóòóññóð úÞ êüéþÓñþòéþõ þðéóêóúéóòè ßèìòÝ þè Øüðóòóññóðè þðï òüØÝþñúèØúÞóðèÛ ú Read the complete document
APPENDIX 1.9 THE SUMMARY OF THE PRODUCT CHARACTERISTICS 1. NAME OF THE MEDICINAL PRODUCT APO-AMOXI CLAV 2. QUALITATIVE AND QUANTITATIVE COMPOSITION with indication of active substances (international nonproprietary name or chemical name), indication of other excipients knowledge of which is essential for safe and proper administration of the medicinal product. COMPONENT AND QUALITY STANDARD (AND GRADE, IF APPLICABLE) FUNCTION OF COMPONENT STRENGTH (LABEL CLAIM) 250/125 MG 500/125 MG 875/125 MG % (OMIT FOR SOLUTIONS) QUANTITY PER UNIT (MG/TABLET) % (OMIT FOR SOLUTIONS) QUANTITY PER UNIT (MG/TABLET) % (OMIT FOR SOLUTIONS) QUANTITY PER UNIT (MG/TABLET) CORE TABLET Amoxicillin Trihydrate USP (Compacted) Active 46.46 300 * 62.31 600 * 73.07 1050 * Clavulanate Potassium and MCC 1 to 1 Active 48.48 313 ** 32.50 313 ** 21.78 313 ** Magnesium Stearate NF Lubricant 0.62 4.0 0.62 6.0 0.63 9 Croscarmellose Sodium NF Disintegrant 1.55 10.0 1.66 16.0 1.67 24 Colloidal Silicon Dioxide NF Glidant and Disintegrant 0.31 2.0 0.31 3.0 0.28 4 FILM COATING Hydroxypropyl Cellulose NF Type LF Film forming polymer 1.17 7.53 1.17 11.3 1.18 16.95 Polyethylene Glycol 8000 NF Plasticizer 0.69 4.47 0.70 6.70 0.70 10.05 Titanium Dioxide USP Colouring Agent/Opacifier 0.72 4.67 0.73 7.00 0.70 10.05 Methanol NF Solvent --- 100.0 --- 150.0 --- 225 TOTAL (EXCLUDING METHANOL): 100 645.67 100 963.00 100.0 1437.05 * 83.3% Amoxicillin on anhydrous basis: Amount required per tablet = Strength in mg per tablet/83.3%. ** 40% Clavulanate: Amount required per tablet = Strength in mg per tablet/40%. 3. PHARMACEUTICAL FORM Tablets 4. CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS APO-AMOXI CLAV (amoxicillin and clavulanate potassium) is indicated for the treatment of the following infections when caused by APO-AMOXI CLAV-susceptible strains of the designated bacteria: Sinusitis when caused by β-lactamase producing strains of _H. _ _influenzae _ or _Moraxella _ _(Branhamella) catarrhalis_._ _ Otitis Media when caused by β-lactamase producing strains of _ H Read the complete document